A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors

Journal of Immunological Methods

Volumn 387, Issue 1-2, 2013, Pages 21-35

  Corrales Aguilar, Eugenia ^a,c   Trilling, Mirko ^a,d   Reinhard, Henrike ^a   Mercé Maldonado, Eva ^a   Widera, Marek ^a   Schaal, Heiner ^a   Zimmermann, Albert ^a   Mandelboim, Ofer ^b   Hengel, Hartmut ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Antibodies; Fc receptors; Viral infections

Indexed keywords

CD3 ANTIGEN; FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IIA; FC RECEPTOR IIIA; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 2; PALIVIZUMAB; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRANULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; HYBRIDOMA CELL CULTURE; IMMUNOASSAY; IN VITRO STUDY; MEASLES VIRUS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD3; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COCULTURE TECHNIQUES; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN G; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; PROTEIN BINDING; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; U937 CELLS; VERO CELLS; VIRUSES;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1; MEASLES VIRUS; RESPIRATORY SYNCYTIAL VIRUS;

EID: 84871423854     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.09.006     Document Type: Article

References (72)

1. Allen J.M., Seed B. Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science (New York, N.Y.) 1989, 243:378.
2. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 2004, 294:15.
3. Atalay R., Zimmermann A., Wagner M., Borst E., Benz C., Messerle M., Hengel H. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J. Virol. 2002, 76:8596.
4. Baum L.L., Cassutt K.J., Knigge K., Khattri R., Margolick J., Rinaldo C., Kleeberger C.A., Nishanian P., Henrard D.R., Phair J. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 1996, 157:2168.
5. Bonifacino J.S., Chen C., Lippincott-Schwartz J., Ashwell J.D., Klausner R.D. Subunit interactions within the T-cell antigen receptor: clues from the study of partial complexes. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6929.
6. Borst E.M., Hahn G., Koszinowski U.H., Messerle M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 1999, 73:8320.
7. Bowles J.A., Weiner G.J. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J. Immunol. Methods 2005, 304:88.
8. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daëron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716.
9. Budt M., Reinhard H., Bigl A., Hengel H. Herpes viral Fcgamma receptors: culprits attenuating antiviral IgG?. Int. Immunopharmacol. 2004, 4:1135.
10. Burton D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2002, 2:706.
11. Cane P.A., Thomas H.M., Simpson A.F., Evans J.E., Hart C.A., Pringle C.R. Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J. Med. Virol. 1996, 48:253.
12. Caputi M., Freund M., Kammler S., Asang C., Schaal H. A bidirectional SF2/ASF- and SRp40-dependent splicing enhancer regulates human immunodeficiency virus type 1 rev, env, vpu, and nef gene expression. J. Virol. 2004, 78:6517.
13. Chu C.-F., Meador M.G., Young C.G., Strasser J.E., Bourne N., Milligan G.N. Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms. J. Reprod. Immunol. 2008, 78:58.
14. Clémenceau B., Congy-Jolivet N., Gallot G., Vivien R., Gaschet J., Thibault G., Vié H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood 2006, 107:4669.
15. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6:443.
16. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22:633.
17. Daëron M., Yodoi J., Néauport-Sautès C., Moncuit J., Fridman W.H. Receptors for immunoglobulin isotypes (FcR) on murine T cells. I. Multiple FcR expression on T lymphocytes and hybridoma T cell clones. Eur. J. Immunol. 1985, 15:662.
18. de Noronha F., Baggs R., Schäfer W., Bolognesi D. Prevention of oncorna virus-induced sarcomas in cats by treatment with antiviral antibodies. Nature 1977, 267:54.
19. Dingwell K.S., Brunetti C.R., Hendricks R.L., Tang Q., Tang M., Rainbow A.J., Johnson D.C. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J. Virol. 1994, 68:834.
20. Dolan A., Cunningham C., Hector R.D., Hassan-Walker A.F., Lee L., Addison C., Dargan D.J., McGeoch D.J., Gatherer D., Emery V.C., et al. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 2004, 85:1301.
21. Dubin G., Socolof E., Frank I., Friedman H.M. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J. Virol. 1991, 65:7046.
22. Farrell H.E., Shellam G.R. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J. Gen. Virol. 1991, 72(Pt 1):149.
23. Forthal D.N., Landucci G., Katz J., Tilles J.G. Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J. Infect. Dis. 1993, 168:1020.
24. Forthal D.N., Landucci G., Habis A., Zartarian M., Katz J., Tilles J.G. Measles virus-specific functional antibody responses and viremia during acute measles. J. Infect. Dis. 1994, 169:1377.
25. Gessner J.E., Heiken H., Tamm A., Schmidt R.E. The IgG Fc receptor family. Ann. Hematol. 1998, 76:231.
26. Gómez-Román V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 2006, 308:53.
27. Hangartner L., Zinkernagel R.M., Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol. 2006, 6:231.
28. Hengel H., Esslinger C., Pool J., Goulmy E., Koszinowski U.H. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. J. Gen. Virol. 1995, 76(Pt 12):2987.
29. Hessell A.J., Hangartner L., Hunter M., Havenith C.E.G., Beurskens F.J., Bakker J.M., Lanigan C.M.S., Landucci G., Forthal D.N., Parren P.W.H.I., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101.
30. Hoetzenecker K., Hacker S., Hoetzenecker W., Sadeghi K., Sachet M., Pollreisz A., Mangold A., Wliszczak T., Bielek E., Muehlbacher F., et al. Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur. J. Clin. Invest. 2007, 37:978.
31. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166:7381.
32. Johnson D.C., Feenstra V. Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin. J. Virol. 1987, 61:2208.
33. Jonjić S., Pavić I., Polić B., Crnković I., Lucin P., Koszinowski U.H. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 1994, 179:1713.
34. Kammler S., Leurs C., Freund M., Krummheuer J., Seidel K., Tange T.O., Lund M.K., Kjems J., Scheid A., Schaal H. The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA. RNA (New York, N.Y.) 2001, 7:421.
35. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (New York, N.Y.) 2006, 313:670.
36. Kantakamalakul W., Pattanapanyasat K., Jongrakthaitae S., Assawadarachai V., Ampol S., Sutthent R. A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals. J. Immunol. Methods 2006, 315:1.
37. Klenovsek K., Weisel F., Schneider A., Appelt U., Jonjic S., Messerle M., Bradel-Tretheway B., Winkler T.H., Mach M. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 2007, 110:3472.
38. Krummheuer J., Lenz C., Kammler S., Scheid A., Schaal H. Influence of the small leader exons 2 and 3 on human immunodeficiency virus type 1 gene expression. Virology 2001, 286:276.
39. Lambotte O., Ferrari G., Moog C., Yates N.L., Liao H.-X., Parks R.J., Hicks C.B., Owzar K., Tomaras G.D., Montefiori D.C., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (London, England) 2009, 23:897.
40. Letourneur F., Malissen B. Derivation of a T cell hybridoma variant deprived of functional T cell receptor alpha and beta chain transcripts reveals a nonfunctional alpha-mRNA of BW5147 origin. Eur. J. Immunol. 1989, 19:2269.
41. Lichtenfels R., Biddison W.E., Schulz H., Vogt A.B., Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 1994, 172:227.
42. Lilley B.N., Ploegh H.L., Tirabassi R.S. Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein. J. Virol. 2001, 75:11218.
43. Lowe D.B., Shearer M.H., Jumper C.A., Bright R.K., Kennedy R.C. Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases. J. Virol. 2007, 81:1313.
44. Mandelboim O., Malik P., Davis D.M., Jo C.H., Boyson J.E., Strominger J.L. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5640.
45. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., Davis D.M., Strominger J.L., Yewdell J.W., Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055.
46. McCullough K.C., Parkinson D., Crowther J.R. Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology 1988, 65:187.
47. Morizono K., Ku A., Xie Y., Harui A., Kung S.K.P., Roth M.D., Lee B., Chen I.S.Y. Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J. Virol. 2010, 84:6923.
48. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 2005, 353:1350.
49. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (New York, N.Y.) 2005, 310:1510.
50. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24:19.
51. Nimmerjahn F., Ravetch J.V. Fc-receptors as regulators of immunity. Adv. Immunol. 2007, 96:179.
52. Osiowy C., Horne D., Anderson R. Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin. Diagn. Lab. Immunol. 1994, 1:670.
53. Parekh B.S., Berger E., Sibley S., Cahya S., Xiao L., Lacerte M.A., Vaillancourt P., Wooden S., Gately D. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 2012, 4.
54. Park-Min K.-H., Serbina N.V., Yang W., Ma X., Krystal G., Neel B.G., Nutt S.L., Hu X., Ivashkiv L.B. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007, 26:67.
55. Parren P.W., Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 2001, 77:195.
56. Polić B., Hengel H., Krmpotić A., Trgovcich J., Pavić I., Luccaronin P., Jonjić S., Koszinowski U.H. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 1998, 188:1047.
57. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 2011, 12:509.
58. Radsak K., Eickmann M., Mockenhaupt T., Bogner E., Kern H., Eis-Hübinger A., Reschke M. Retrieval of human cytomegalovirus glycoprotein B from the infected cell surface for virus envelopment. Arch. Virol. 1996, 141:557.
59. Ravetch J.V., Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 2001, 19:275.
60. Sanna P.P., Burton D.R. Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J. Virol. 2000, 74:9813.
61. Schaal H., Pfeiffer P., Klein M., Gehrmann P., Scheid A. Use of DNA end joining activity of a Xenopus laevis egg extract for construction of deletions and expression vectors for HIV-1 Tat and Rev proteins. Gene 1993, 124:275.
62. Shore S.L., Cromeans T.L., Romano T.J. Immune destruction of virus-infected cells early in the infectious cycle. Nature 1976, 262:695.
63. Snydman D.R., Werner B.G., Heinze-Lacey B., Berardi V.P., Tilney N.L., Kirkman R.L., Milford E.L., Cho S.I., Bush H.L., Levey A.S. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 1987, 317:1049.
64. Sprague E.R., Reinhard H., Cheung E.J., Farley A.H., Trujillo R.D., Hengel H., Bjorkman P.J. The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J. Virol. 2008, 82:3490.
65. Stengelin S., Stamenkovic I., Seed B. Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning. EMBO J. 1988, 7:1053.
66. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531.
67. Wagner M., Jonjic S., Koszinowski U.H., Messerle M. Systematic excision of vector sequences from the BAC-cloned herpes virus genome during virus reconstitution. J. Virol. 1999, 73:7056.
68. Wegener A.M., Letourneur F., Hoeveler A., Brocker T., Luton F., Malissen B. The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 1992, 68:83.
69. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896.
70. Woof J.M., Burton D.R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 2004, 4:89.
71. Wright D.E., Colaco S., Colaco C., Stevenson P.G. Antibody limits in vivo murid herpes virus-4 replication by IgG Fc receptor-dependent functions. J. Gen. Virol. 2009, 90:2592.
72. Wu H., Pfarr D.S., Tang Y., An L.-L., Patel N.K., Watkins J.D., Huse W.D., Kiener P.A., Young J.F. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 2005, 350:126.